In the face of unprecedented cost-per-patient expenses, the FDA's recent focus on rare disease, and a myriad of options for identifying, engaging, screening, and retaining...

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an...

Uniting Large Pharma, Innovative Biotech and Leading Academics to Eliminate the Boundaries of Druggability with Novel Covalent Drugs With continued advancements in screening...

With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field...

Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors The complement community is shifting gear, with more companies than ever targeting alternative...